Ashish Goyal

Dr. Ashish Goyal

orcid

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2020 in Science Advances
Verified
Journal Article
Open access
PDF file
AGAshish Goyal
Ashish Goyal
ECErwing Fabian Cardozo-Ojeda
Erwing Fabian Cardozo-Ojeda
JSJoshua T. Schiffer
Joshua T. Schiffer
We developed a mathematical model to predict the outcomes of different possible COVID-19 treatments.

1 October 2017 in Journal of King Saud University – Science
Verified
Journal Article
Open access
AGAshish Goyal
Ashish Goyal
The present investigation focuses the effect of process parameters on material removal rate (MRR) and surface roughness (Ra) in wire electric discharge machining of Inconel 625. Machining was done by using a normal zinc coated wire and cryogenic treated zinc coated wire. The experiments were performed by considering different process parameters viz. tool electrode, current intensity, pulse on time, pulse off time, wire feed and wire tension. The thickness of work material and dia. of wire are kept constant. Taguchi L18 (21 * 35) orthogonal array of experimental design is used to perform the experiments. Analysis of variance (ANOVA) is employed to optimize the material removal rate and surface roughness. Based on analysis it is found that pulse on time, tool electrode and current intensity are the significant parameters that affect the material removal rate and surface roughness. The scanning electron microscopy (SEM) are used to identify the microstructure of the machined work piece

1 February 2015 in Journal of Theoretical Biology
Verified
Journal Article
Closed access
JMJohn Murray
John Murray
AGAshish Goyal
Ashish Goyal

14 October 2014 in PLOS ONE
Verified
Journal Article
Open access
PDF file
AGAshish Goyal
Ashish Goyal
JMJohn Murray
John Murray
The major cause of liver cancer around the globe is hepatitis B virus (HBV), which also contributes to a large number of deaths due to liver failure alone. Hepatitis delta virus (HDV) is as potentially alarming as HBV since life threatening cases are 10 times more likely with HBV-HDV dual infection compared to HBV monoinfection. So far, there is no established effective treatment against HDV and the only preventive action suggested by the World Health Organization is to introduce HBV vaccination for children immediately after birth (newborns) and thus reduce the available pool for HDV infection. Here the main objective is to understand the complex dynamics of HBV-HDV infection in a human population that can inform public health policy makers on the level of different preventive measures required to eliminate HBV and HDV infections. Model simulations suggest that HBV vertical transmission and HBV vaccination rates for newborns are instrumental in determining HBV and HDV prevalence. A decrease in HBV prevalence is observed as vaccination coverage increases and it is possible to eradicate both HBV and HDV using high vaccination coverage of ≥80% in the long term. We further found that HDV presence results in lower HBV prevalence. An application of our model to China revealed that vaccinating every newborn in China will further prevent 1.69 million new infections by 2028 as compared to the current 90% vaccination coverage. Although, higher vaccination coverage of newborns should eliminate both HBV and HDV over a long time period, any short term strategy to eradicate HDV must include additional preventive measures such as HBV adult vaccination. Implementation of HBV adult vaccination programs at a rate of 10% per year over 15 years will further prevent 39 thousand new HDV infections in China by 2028 as compared to HBV vaccination programs solely for newborns.

10 September 2018 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
AKAbraham J. Kandathil
Abraham J. Kandathil
SSSho Sugawara
Sho Sugawara
AGAshish Goyal
Ashish Goyal
CDChristine M. Durand
Christine M. Durand
JQJeffrey Quinn
Jeffrey Quinn
ABAshwin Balagopal
Ashwin Balagopal
Long-lived HIV-1 reservoirs that persist despite antiretroviral therapy (ART) are a major impediment to a cure for HIV-1. We examined whether human liver macrophages (LMs), the largest tissue macrophage population, comprise an HIV-1 reservoir. We purified LMs from liver explants and included treatment with a T cell immunotoxin to reduce T cells to 1% or less. LMs were purified from 9 HIV-1–infected persons, 8 of whom were on ART (range 8–140 months). Purified LMs were stimulated ex vivo and supernatants from 6 of 8 LMs from persons on ART transmitted infection. However, HIV-1 propagation from LMs was not sustained except in LMs from 1 person taking ART for less than 1 year. Bulk liver sequences matched LM-derived HIV-1 in 5 individuals. Additional in vitro experiments undertaken to quantify the decay of HIV-1–infected LMs from 3 healthy controls showed evidence of infection and viral release for prolonged durations (>170 days). Released HIV-1 propagated robustly in target cells, demonstrating that viral outgrowth was observable using our methods. The t1/2 of HIV-1–infected LMs ranged from 3.8–55 days. These findings suggest that while HIV-1 persists in LMs during ART, it does so in forms that are inert, suggesting that they are defective or restricted with regard to propagation.

2 November 2019 in Current Opinion in Systems Biology
Verified
Journal Article
Closed access
AGAshish Goyal
Ashish Goyal
LLLaura E. Liao
Laura E. Liao
APAlan S. Perelson
Alan S. Perelson